InnoCan Pharma Past Earnings Performance
Past criteria checks 0/6
InnoCan Pharma has been growing earnings at an average annual rate of 7.1%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 120.6% per year.
Key information
7.1%
Earnings growth rate
22.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 120.6% |
| Return on equity | -95.0% |
| Net Margin | -27.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How InnoCan Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 19 | -5 | 19 | 2 |
| 31 Dec 23 | 14 | -5 | 14 | 2 |
| 30 Sep 23 | 10 | -5 | 11 | 2 |
| 30 Jun 23 | 7 | -3 | 9 | 1 |
| 31 Mar 23 | 4 | -4 | 7 | 2 |
| 31 Dec 22 | 3 | -4 | 7 | 2 |
| 30 Sep 22 | 1 | -3 | 7 | 1 |
| 30 Jun 22 | 1 | -7 | 7 | 1 |
| 31 Mar 22 | 0 | -6 | 6 | 1 |
| 31 Dec 21 | 0 | -10 | 6 | 1 |
| 30 Sep 21 | 0 | -16 | 5 | 2 |
| 30 Jun 21 | 0 | -14 | 4 | 2 |
| 31 Mar 21 | 0 | -14 | 4 | 2 |
| 31 Dec 20 | 0 | -10 | 3 | 2 |
| 30 Sep 20 | 0 | -3 | 3 | 1 |
| 30 Jun 20 | 0 | -5 | 4 | 1 |
| 31 Mar 20 | 0 | -3 | 3 | 1 |
| 31 Dec 19 | 0 | -3 | 3 | 0 |
| 30 Sep 19 | 0 | -6 | 3 | 1 |
Quality Earnings: IP4 is currently unprofitable.
Growing Profit Margin: IP4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IP4 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.1% per year.
Accelerating Growth: Unable to compare IP4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IP4 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: IP4 has a negative Return on Equity (-95.05%), as it is currently unprofitable.